Psychiatr. pro Praxi, 2004; 3: 111-117

Amisulprid u dystýmie a úzkostných poruch - východiska a kazuistiky

doc. MUDr. Ján Praško CSc1,3,2,4, MUDr. Richard Záleský1, Mgr. Petra Houbová1, MUDr. Erik Herman5,7,6, doc. MUDr. Jiří Hovorka CSc6,8
1 Psychiatrické centrum Praha, 3. LF UK, Praha
2 Centrum neuropsychiatrických studií, Praha
3 Psychiatrická klinika FN a LF UP, Olomouc
4 3. LF UK, Praha
5 Psychiatrická klinika 1. LF UK a VFN Praha
6 Neurologické oddělení, neuropsychiatrické a epileptologické centrum, Nemocnice Na Františku s poliklinikou, Praha
7 Psychiatrická ambulance, Praha
8 Neurochirurgická klinika 1. LF UK, Praha

Keywords: dopamine, nucleus accumbens, reward system, amisulpride, dysthymia, social phobia.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Praško J, Záleský R, Houbová P, Herman E, Hovorka J. Amisulprid u dystýmie a úzkostných poruch - východiska a kazuistiky. Psychiatr. praxi. 2004;9(3):111-117.

Dopaminergní systém má pravděpodobně klíčovou roli v motivaci a jejím posilování a může mít také roli u deprese a úzkostných poruch (zejména sociální fobie). Řada antidepresiv potencuje dopaminergní neurotransmisi v nucleus accumbens. Dopaminergní hypofunkce může být obzvlášť důležitá u pacientů trpících psychomotorickou retardací a anhedonií. Důkazy ukazují na roli dopaminu také u sociální fobie. Dopaminergní látky jako je amisulprid nebo bupropion, v monoterapii nebo v kombinaci se serotonergními látkami, mohou pomoci překonat farmakoresistenci u pacientů trpících dystymií, depresí nebo úzkostnými poruchami.

Amisulprid in dysthymia and anxiety disorders - resources and case reports

The dopamine system is thought to play a crucial role in processing motivation and reward, and may also play a role in depression and anxiety disorders (especially social phobia). Interestingly, a range of antidepressants potentiate dopamine transmission in the nucleus accumbens. Dopamine hypofunction may be particularly important in patients with psychomotor retardation and anhedonia. A range of evidence points to the involvement of the dopaminergic system in social phobia. Dopaminergic agents, such as amisulpride or bupropion, in monotherapy or in combination with serotonergic agents can help overcome pharmacoresistance in patients suffering from dysthymia, depression or anxiety disorders.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Akiskal HS. Dysthymia: clinical and external validity. Acta Psychiatr Scand 1994; 383: 19-23. Go to original source... Go to PubMed...
    2. Akiskal HS. Dysthymia, cyclothymia, and related chronic subtreshold mood disorders. In: Geodet MG, López - Ibor, JJ a Andreasen NC: New Oxford Textbook of Psychiatry, Oxford University Press 2000; 736-749.
    3. Amore M, Jori MC: Faster response on amisulprid 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double - blind, parallel group study. Int Clin Psychopharmacology 2001; 16: 317-324. Go to original source... Go to PubMed...
    4. Arias F, Padin JJ, Gilberte I, Sanches R, Gomez S, Garcia D: Comparative efficacy and tolerability among different selective serotoninu re-uptake inhibitors and venlafaxine in a naturalistic setting. Int J Psychiatry Clin Prac 1998; 2: 255-260. Go to original source... Go to PubMed...
    5. Bogetto F, Barzega H, Bellino S, Maina G, Ravizza L. Drug treatment of dysthymia: A clinical study. Rivista di Psychiatria 1997; 32: 1-5.
    6. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999; 39: 25-32. Go to original source... Go to PubMed...
    7. Brown SL, Steinberg RL a van Praag HM. The pathogenesis of depression: reconsideration of neurotransmitter data. In: den Boer JA a Sitsen JMA (eds): Handbook of Depression and Anxiety. Marcel Dekker, New York 1994; 317-347.
    8. Cummings JL. Psychosomatic aspects of movement disorders. Adv Psychosom Med 1985; 13: 111-132. Go to original source... Go to PubMed...
    9. Diana M, Melis M, Muntonni AL a spol. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 1998; 95: 10269-10273. Go to original source... Go to PubMed...
    10. Dunner DL, Schmaling KB, Hendrickson H, Becker J, Lehman A, Bea C. Cognitive therapy versus fluoxetin in the treatment of dysthymic disorder. Depression 1996; 4: 34-41. Go to original source... Go to PubMed...
    11. Dunner DL, Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. J Clin Psychiatry 1997; 58: 528-531. Go to original source... Go to PubMed...
    12. Emmanuel NP, Lydiard BR, Ballanger JC: Treatments of social phobia with bupropion. J Clin Psychopharmacol 1991; 1: 276-277. Go to original source... Go to PubMed...
    13. Fredholm BB, Battig K, Holmen J, a spol. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133. Go to PubMed...
    14. Gruber AJ, Pope HG. Substance abuse: cannabis-related disorders. In: Tasman A, Kay J, Lieberman JA (eds): Psychiatry, Second ed. Wiley & Sons, Chichester 2003; 995-1009.
    15. Gruenberg AM a Goldstein RD. Mood disorders: Depression. In: Tasman A, Kay J, Lieberman JA (eds): Psychiatry, Second ed. Wiley & Sons, Chichester 2003; 1207-1236.
    16. Hellerstein DJ, Samstag LW, Little S a Xanowitch P. Dysthymia: Assessing symptoms and treatment response with the Cornell Dysthymia Rating Scale. Presented at the Annual meeting, American Psychiatric Assn., Philadelphia, May 21-26 (New research program and abstrakt p 111) 1994.
    17. Hellerstein DJ, Batchelder S, Kreditor D, Fedak M. Bupropion sustained-release for the treatment of dysthymic disorder: An open-label study. J Clin Psychopharmacol 2001; 21: 325-329. Go to original source... Go to PubMed...
    18. Hemby SE. Recent advances in the biology of addiction. Curr Psychiatr Rep 1999; 1: 180-187. Go to original source... Go to PubMed...
    19. Hovorka J, Herman E, Praško J, Doubek P. Dystymie a depresivní příznaky v neurologii. Naše zkušenosti s kombinovanou léčbou SSRI a amisulpridem (Deniban) u organických mozkových onemocnění v neurologii. ČS Neurologie a Neurochirurgie 2004; 67: 1: tématická příloha 1-15.
    20. Kapur S a Mann JJ. Role of dopaminergic system in depression. Biol Psychiatr 1992; 32: 1-17. Go to original source... Go to PubMed...
    21. Keller M a Shapiro RW., ,Double depression"; Superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatry 1982; 139: 438-442. Go to original source... Go to PubMed...
    22. Kessler RC, McGonagle KA a Zhao S. Lifetime and 12-months prevalence of DSM-III-R psychiatric disorders in United States. Arch Gen Psychiatr 1994; 51: 8-19. Go to original source... Go to PubMed...
    23. King RJ, Mefford IN a Wang C. CSF dopamine levels correlate with extraversion in depressed patients. Psychiatr Res 1986; 19: 305-310. Go to original source... Go to PubMed...
    24. Koukolík F. Lidský mozek. Funkční systémy. Norma a poruchy. Portál, Praha 2002; 451s.
    25. Lecrubier Y, Boyer P, Turjanski S, Rein W: Amisulpride study group: amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disorder 1997; 43: 95-103. Go to original source... Go to PubMed...
    26. Lee HS, Kim SH, Suh KY, Klak DI. Efficacy of sertraline in dysthymia. Presented at the XIXth CINP Congress, Washington DC, June 27 - July 1. Neuropsychopharmacology 10 (No 3S/Part 2) 1994; 222S.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.